Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Beelen, Dietrich W. ; Stelljes, Matthias ; Reményi, Péter ; Wagner‐Drouet, Eva‐Maria ; Dreger, Peter ; Bethge, Wolfgang ; Ciceri, Fabio ; Stölzel, Friedrich ; Junghanß, Christian ; Labussiere‐Wallet, Hélène ; Schaefer‐Eckart, Kerstin ; Grigoleit, Goetz U. ; Scheid, Christof ; Patriarca, Francesca ; Rambaldi, Alessandro ; Niederwieser, Dietger ; Hilgendorf, Inken ; Russo, Domenico ; Socié, Gérard ; Holler, Ernst ; Glass, Bertram ; Casper, Jochen ; Wulf, Gerald ; Basara, Nadezda ; Bieniaszewska, Maria ; Stuhler, Gernot ; Verbeek, Mareike ; La Rocca, Ursula ; Finke, Jürgen ; Benedetti, Fabio ; Pichlmeier, Uwe ; Klein, Anja ; Baumgart, Joachim ; Markiewicz, Miroslaw

---

Alternative Links zum Volltext:DOIVerlag

---

Details

Dokumentenart:	Artikel
Titel eines Journals oder einer Zeitschrift:	American Journal of Hematology
Verlag:	WILEY
Ort der Veröffentlichung:	HOBOKEN
Band:	97
Nummer des Zeitschriftenheftes oder des Kapitels:	8
Seitenbereich:	S. 1023-1034
Datum:	2022
Institutionen:	Medizin > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Identifikationsnummer:	Wert Typ 10.1002/ajh.26620 DOI
Stichwörter / Keywords:	VERSUS-HOST-DISEASE; CONDITIONING INTENSITY; FLUDARABINE; RECOMMENDATIONS; MANAGEMENT; DIAGNOSIS; MELPHALAN; REGIMEN; MARROW; IMPACT;
Dewey-Dezimal-Klassifikation:	600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
Status:	Veröffentlicht
Begutachtet:	Ja, diese Version wurde begutachtet
An der Universität Regensburg entstanden:	Ja
Dokumenten-ID:	57776

Indiziert in

Web of Science

Bibliographische Daten exportieren

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreDublin Core (LZV)EndNoteHTML CitationJSONJSON LDMETSMODSOPENAIREOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLxMetaDissPlus

---

Zusammenfassung

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of ...

Zusammenfassung

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical study including 476 patients demonstrated statistically significant noninferiority for treosulfan with clinically meaningful improvement in EFS. Here, the final study results and pre-specified subgroup analyses of all 570 randomized patients with completed longer-term follow-up are presented. Patients presenting HCT-specific comorbidity index >2 or aged >= 50 years were randomly assigned (1:1) to intravenous (IV) fludarabine with either treosulfan (30 g/m(2) IV) or busulfan (6.4 mg/kg IV) after stratification by disease risk group, donor type, and participating institution. The primary endpoint was EFS with disease recurrence, graft failure, or death from any cause as events. EFS of patients (median age 60 years) was superior after treosulfan compared to RIC busulfan: 36-months-EFS rate 59.5% (95% CI, 52.2-66.1) vs. 49.7% (95% CI, 43.3-55.7) with a hazard ratio (HR) of 0.64 (95% CI, 0.49-0.84), p = 0.0006. Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-month-OS rate 66.8% vs. 56.3%; HR 0.64 (95% CI, 0.48-0.87), p = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.

---

---

Metadaten zuletzt geändert: 29 Feb 2024 13:02

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Altmetric

Altmetric

Altmetric

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)